The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said on 23 February 2021 that Mexico, the first country in North America to approve Russia's Sputnik V COVID-19 vaccine, has received its first batch of the vaccine, CNN reported on Tuesday.
In a statement, the RDIF said: "On 3 February 2021, the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the emergency use authorisation procedure without additional clinical trials in the country."
Kirill Dmitriev, CEO of the RDIF, said: "it is a significant breakthrough in Russia's efforts to fight COVID-19 and clearly shows that saving lives is above politics."
According to figures from the RDIF, which oversees global distribution and sales of the vaccine, Russia's Sputnik V COVID-19 vaccine has now been approved for use in more than 30 countries and is one of the world's most pre-ordered vaccines, with at least 50 countries, from Argentina to the Philippines, ordering nearly 2.5 billion doses so far.
A tally by Johns Hopkins University has revealed that Mexico has the third highest death toll in the world, behind the US and Brazil, with more than 180,000 deaths.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine